Display options
Cite
Zhao W, Ho WT, Zhao ZJ. Quantitative analyses of myelofibrosis by determining hydroxyproline. Stem Cell Investig. 2015;2:2doi: 10.3978/j.issn.2306-9759.2015.01.02.
Zhao, W., Ho, W. T., & Zhao, Z. J. (2015). Quantitative analyses of myelofibrosis by determining hydroxyproline. Stem cell investigation, 22. https://doi.org/10.3978/j.issn.2306-9759.2015.01.02
Zhao, Wanke, et al. "Quantitative analyses of myelofibrosis by determining hydroxyproline." Stem cell investigation vol. 2 (2015): 2. doi: https://doi.org/10.3978/j.issn.2306-9759.2015.01.02
Zhao W, Ho WT, Zhao ZJ. Quantitative analyses of myelofibrosis by determining hydroxyproline. Stem Cell Investig. 2015 Jan 26;2:2. doi: 10.3978/j.issn.2306-9759.2015.01.02. eCollection 2015. PMID: 27358870; PMCID: PMC4923646.
Copy Download .nbib Format: NLM
Share it on

Stem Cell Investig. 2015 Jan 26;2:2. doi: 10.3978/j.issn.2306-9759.2015.01.02. eCollection 2015.

Quantitative analyses of myelofibrosis by determining hydroxyproline.

Stem cell investigation

Wanke Zhao, Wan-Ting Tina Ho, Zhizhuang Joe Zhao

Affiliations

  1. Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.

PMID: 27358870 PMCID: PMC4923646 DOI: 10.3978/j.issn.2306-9759.2015.01.02

Abstract

BACKGROUND: Myeloproliferative neoplasms (MPNs) are blood malignancies manifested in increased production of red blood cells, white blood cells, and/or platelets. Myelofibrosis is a subtype of MPNs characterized by the formation of scar-like tissues in the bone marrow due to abnormal hematopoiesis. It is considered a disease of both hematopoietic stem cells and stem cell niches. Patients with myelofibrosis have very poor prognosis, and there is no effective treatment so far. Myelofibrosis has routinely been detected by using histochemical staining methods which produce qualitative rather than quantitative results. In this study, we developed a quantitative assay of bone marrow myelofibrosis in JAK2V617F transgenic mice by determining hydroxyproline.

METHODS: The JAK2V617F transgenic mice's tissue was collected to detect the bone marrow myelofibrosis. Statistical analyses were performed using the GraphPad Prism program. Differences of samples between two groups were accessed using t tests. P values less than 0.05 (2-tailed) were considered significantly different.

RESULTS: We developed a quantitative method for detecting myelofibrosis by analyzing the content of hydroxyproline, a modified amino acid largely restricted to collagen which forms the fibrotic structure in bone marrow tissues. Our study also demonstrated age-dependent development of bone marrow myelofibrosis in JAK2V617F transgenic mice.

CONCLUSIONS: In the present study, we have developed a new method for detecting bone marrow myelofibrosis by analyzing hydroxyproline contents. The method is highly sensitive and accurate. It provides more accurate, representative, and quantitative information than histochemical analyses. We believe that this method should find wide applications for analyzing the progression of myelofibrosis and efficacy of drug treatment.

Keywords: Myelofibrosis; hydroxyproline; method

References

  1. J Hematol Oncol. 2014 Mar 19;7:25 - PubMed
  2. Blood. 2008 May 15;111(10):5109-17 - PubMed
  3. Blood. 2008 Sep 15;112(6):2190-8 - PubMed
  4. Blood. 2010 Apr 29;115(17):3589-97 - PubMed
  5. Cancer Cell. 2005 Apr;7(4):387-97 - PubMed
  6. Clin Chim Acta. 2006 Jun;368(1-2):48-52 - PubMed
  7. Cell Tissue Res. 2010 Jan;339(1):247-57 - PubMed
  8. Br J Haematol. 2007 Nov;139(3):351-62 - PubMed
  9. Blood. 2010 Sep 2;116(9):1528-38 - PubMed
  10. J Endocrinol Invest. 2005;28(10 Suppl):8-13 - PubMed
  11. Leukemia. 2008 Jan;22(1):3-13 - PubMed
  12. Clin Chim Acta. 1967 Nov;18(2):267-73 - PubMed
  13. Leukemia. 2008 Jan;22(1):87-95 - PubMed
  14. Blood. 2008 Oct 15;112(8):3026-35 - PubMed
  15. Cancer Cell. 2010 Jun 15;17(6):584-96 - PubMed
  16. J Biol Chem. 2005 Jun 17;280(24):22788-92 - PubMed
  17. Br J Haematol. 1979 Feb;41(2):151-61 - PubMed
  18. Blood. 1980 Mar;55(3):383-5 - PubMed
  19. Blood. 2008 Apr 15;111(8):3931-40 - PubMed
  20. N Engl J Med. 2005 Apr 28;352(17):1779-90 - PubMed
  21. Lancet. 2005 Mar 19-25;365(9464):1054-61 - PubMed
  22. Clin Biochem. 1996 Jun;29(3):225-9 - PubMed
  23. Nature. 2005 Apr 28;434(7037):1144-8 - PubMed
  24. PLoS One. 2013 Dec 31;8(12):e84340 - PubMed
  25. J Immunol. 2014 Jul 15;193(2):477-84 - PubMed
  26. N Engl J Med. 2006 Dec 7;355(23):2452-66 - PubMed
  27. Blood. 2010 Aug 5;116(5):783-7 - PubMed

Publication Types